Serum proteins in chronic hepatitis B patients treated with peginterferon alfa-2b

doi:10.3748/wjg.v19.i31.5067

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 31

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5544)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-4) series.

Item

Count

PDF

338

HTML

3047

Figures (1-4)

206

Tables (1-4)

143

Sum=3734

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

907

Download

903

Sum=1810

Aug 21, 2013 (publication date) through Apr 18, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Original Article

World J Gastroenterol. Aug 21, 2013; 19(31): 5067-5075
Published online Aug 21, 2013. doi: 10.3748/wjg.v19.i31.5067

Serum proteins in chronic hepatitis B patients treated with peginterferon alfa-2b

Sunida Kuakarn, Poorichaya SomParn, Pisit Tangkijvanich, Varocha Mahachai, Visith Thongboonkerd, Nattiya Hirankarn

Sunida Kuakarn, Medical Microbiology, Interdisciplinary Program, Graduate School, Chulalongkorn University, Bangkok 10330, Thailand

Poorichaya SomParn, Nattiya Hirankarn, Immunology Unit, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand

Pisit Tangkijvanich, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand

Varocha Mahachai, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand

Visith Thongboonkerd, Medical Proteomics Unit, Office for Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

Visith Thongboonkerd, Center for Research in Complex Systems Science, Mahidol University, Bangkok 10700, Thailand

Author contributions: Kuakarn S performed the majority of experiments; SomParn P and Thongboonkerd V provided analytical tools and were also involved in editing the manuscript; Tangkijvanich P and Mahachai V provided the collection of samples in addition to providing financial support for this work; Hirankarn N designed the study and wrote the manuscript.

Supported by The 90^th Anniversary of Chulalongkorn University Fund (Ratchadaphiseksomphot Endowment Fund); The Thailand Research Fund, No. RMU5180051; The Thailand Research Fund Senior Research Scholarship, No. RTA5380005; The Higher Education Research Promotion and National Research University Project of Thailand, Office of the Higher Education Commission, No. HR1163A; Integrated Innovation Academic Center, Chulalongkorn University Centenary Academic Development Project, No. CU56-HR05, The Liver Research Unit, Chulalongkorn University

Correspondence to: Nattiya Hirankarn, MD, PhD, Immunology Unit, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, 254 Phayathai Road, Pathumwan, Bangkok 10330, Thailand. nattiyap@gmail.com

Telephone: +66-2-2564132 Fax: +66-2-2525952

Received: January 21, 2013
Revised: June 6, 2013
Accepted: June 19, 2013
Published online: August 21, 2013

Core Tip

Core tip: Serum proteins serve as non-invasive biomarkers for several diseases. This is the first report on the potential use of common protein levels in the serum of chronic hepatitis B (CHB) patients to predict treatment responsiveness to peginterferon alfa-2b. We identified 2 potential serum biomarkers, alpha-2-HS-glycoprotein and complement component C3c, that can be used to predict treatment outcome in patients with CHB receiving peginterferon alfa-2b. The identification of these biomarkers prior to treatment is preferable in order to avoid systemic side effects due to interferon therapy.